{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:01:00Z","timestamp":1753891260211,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Secondary hyperparathyroidism (SHPT) in dialysis is common. A young man on chronic hemodialysis with SHPT developed pancytopenia with resistant anemia requiring transfusions. A bone marrow biopsy showed grade 3 fibrosis, depleted cellularity, osteosclerosis, and decreased myelopoiesis. He initiated Etelcalcetide 7\u22c55 mg 3 times weekly with improvement in SHPT concomitant with near normalization of blood counts. Marrow biopsy at 12 months showed clearance of marrow reticulin, improvement of osteosclerosis and normalization of bone trabeculae, cellularity and myelopoiesis. This is a unique case in which Etelcalcetide treatment is comparable to parathyroidectomy on SHPT and is associated with significant improvement in severe myelofibrosis.<\/jats:p>","DOI":"10.3389\/fmed.2022.1050062","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:05:42Z","timestamp":1677132342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report"],"prefix":"10.3389","volume":"9","author":[{"given":"Vincenzo Antonio","family":"Panuccio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Tripepi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Postorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Greve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sabattini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther Natalie","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.ajkd.2019.07.013","article-title":"Symptoms of secondary hyperparathyroidism in patients receiving maintenance hemodialysis: a prospective cohort study.","volume":"75","author":"Levy","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters.","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.10.041","article-title":"Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007.","volume":"57","author":"Li","year":"2011","journal-title":"Am J Kidney Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.34067\/KID.0000772020","article-title":"Parathyroid hormone serum levels and mortality among hemodialysis patients in the gulf cooperation council countries: results from the DOPPS (2012\u20132018).","volume":"1","author":"Al Salmi","year":"2020","journal-title":"KIDNEY360."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","article-title":"Fractures in patients with CKD\u2014diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.","volume":"92","author":"Pimentel","year":"2017","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"crossref","first-page":"v2","DOI":"10.1093\/ndt\/gfh1049","article-title":"The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes.","volume":"19","author":"Horl","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"B7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/1744-9987.12685","article-title":"Emerging association between parathyroid hormone and anemia in hemodialysis patients.","volume":"22","author":"Tanaka","year":"2018","journal-title":"Ther Apher Dial."},{"key":"B8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1056\/NEJM199301213280304","article-title":"Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.","volume":"328","author":"Rao","year":"1993","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ekir.2018.04.003","article-title":"Myelofibrosis-induced erythropoietin-resistant anemia due to severe refractory hyperparathyroidism.","volume":"3","author":"Sethi","year":"2018","journal-title":"Kidney Int Rep."},{"key":"B10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2265.2008.03346.x","article-title":"Anaemia and marrow fibrosis in patients with primary hyperparathyroidism before and after curative parathyroidectomy.","volume":"70","author":"Bhadada","year":"2009","journal-title":"Clin Endocrinol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial.","volume":"317","author":"Block","year":"2017","journal-title":"Clin Trial JAMA."},{"key":"B12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/ckj\/sfaa005","article-title":"Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics.","volume":"14","author":"Arenas","year":"2020","journal-title":"Clin Kidney J."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1050062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:05:48Z","timestamp":1677132348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1050062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":12,"alternative-id":["10.3389\/fmed.2022.1050062"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1050062","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"1050062"}}